A detailed history of China Universal Asset Management Co., Ltd. transactions in Mirum Pharmaceuticals, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 9,176 shares of MIRM stock, worth $424,481. This represents 0.04% of its overall portfolio holdings.

Number of Shares
9,176
Previous 5,537 65.72%
Holding current value
$424,481
Previous $189,000 88.89%
% of portfolio
0.04%
Previous 0.03%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$33.68 - $44.74 $122,561 - $162,808
3,639 Added 65.72%
9,176 $357,000
Q2 2024

Jul 19, 2024

SELL
$23.57 - $34.85 $80,491 - $119,012
-3,415 Reduced 38.15%
5,537 $189,000
Q1 2024

Apr 29, 2024

BUY
$24.92 - $30.02 $88,665 - $106,811
3,558 Added 65.96%
8,952 $225,000
Q4 2023

May 21, 2024

SELL
$27.14 - $34.93 $96,564 - $124,280
-3,558 Reduced 39.75%
5,394 $159,000
Q4 2023

Jan 23, 2024

BUY
$27.14 - $34.93 $119,633 - $153,971
4,408 Added 447.06%
5,394 $159,000
Q3 2023

May 21, 2024

BUY
$24.63 - $32.85 $12,019 - $16,030
488 Added 97.99%
986 $31,000
Q3 2023

Oct 30, 2023

BUY
$24.63 - $32.85 $12,019 - $16,030
488 Added 97.99%
986 $31,000
Q2 2023

May 21, 2024

SELL
$23.51 - $30.09 $23 - $30
-1 Reduced 0.2%
498 $12,000
Q2 2023

Jul 27, 2023

SELL
$23.51 - $30.09 $23 - $30
-1 Reduced 0.2%
498 $13,000
Q1 2023

May 21, 2024

BUY
$19.19 - $24.1 $2,398 - $3,012
125 Added 33.42%
499 $11,000
Q1 2023

Apr 27, 2023

BUY
$19.19 - $24.1 $2,398 - $3,012
125 Added 33.42%
499 $12,000
Q4 2022

May 21, 2024

SELL
$17.59 - $23.83 $150,887 - $204,413
-8,578 Reduced 95.82%
374 $7,000
Q4 2022

Jan 31, 2023

BUY
$17.59 - $23.83 $510 - $691
29 Added 8.41%
374 $7,000
Q3 2022

Oct 21, 2022

BUY
$19.98 - $29.44 $6,893 - $10,156
345 New
345 $7,000

Others Institutions Holding MIRM

About Mirum Pharmaceuticals, Inc.


  • Ticker MIRM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,751,700
  • Market Cap $1.7B
  • Description
  • Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...
More about MIRM
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.